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mately 3400 cases in the study. Age (<65>), sex, urgency
of admission and four co-morbidities were selected a
priori for sub-group analyses; diabetes mellitus, acute MI,
renal failure and dysrhythmia. Charges were converted to
costs using the U.S. CMS cost-to-charge ratio of 0.3574.
Economic data and the rates of clinical outcomes were
drawn from the Center’s patient-level data. Multi-factor
regressions were conducted to determine the incremental
effects of the four co-morbidities. Statistical signiﬁcance
and conﬁdence intervals were calculated for each 
endpoint. 
RESULTS: Average costs from admit to discharge were
$7,642 in total and pharmacy was $525 (p value <.05).
The geometric mean outcome rates were: death 0.8%,
2nd MI following PTCA 2.4%, revascularization proce-
dures 3.2%, hemorrhage 8.7%, transfusion 3.4% and
thrombocytopenia 1.3%. The sub-group with the highest
costs and worst clinical outcomes were women, urgently
admitted, > 65 years old who had renal failure, acute MI,
or dysrhythmia, in descending impact. 
CONCLUSION: The analyses provide a baseline to assess
the future impact of a new medication on the formulary,
as well as a basis to evaluate a new business agreement.
The economic and clinical analyses will be repeated 
following the new medication’s usage, and will then be
evaluated by the Center’s healthcare personnel in a group
session.
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OBJECTIVES: Capecitabine-docetaxel (CD) combina-
tion therapy signiﬁcantly prolongs time to disease 
progression and overall survival, compared with 
docetaxel monotherapy (D). This study assessed the 
cost-effectiveness of CD versus D from perspective of 
a US health delivery organization. 
METHODS: The model is based on analyses of a 
2-armed, balanced, multicenter, randomized trial of 
CD compared with D for the treatment of advanced
anthracycline-pretreated breast cancer (n = 511). Mean
time to progression and mean survival were estimated
using Kaplan-Meier methods. Data were collected on hos-
pital resource use data, infusions, drug use, and number
of consultations. Adjustments for QoL and cost per unit
of resources were based on published data. The uncer-
tainty in the cost-effectiveness was estimated using Monte
Carlo simulation methods. 
RESULTS: CD resulted in longer mean duration of 
treatment (129 days) than D (98 days). Patients lived an
average of 80 days longer with CD and experienced 64
days longer progression-free survival. No signiﬁcant 
differences were observed in medication use and con-
sultations. Patients receiving CD had fewer treatment-
related hospitalization days (4.8 days versus 5.5 days per
patient). Because of the lower planned docetaxel dose in
the combination arm (75 vs. 100mg/m2), the cumulative
dose of docetaxel was 648mg in combination, compared
with 847mg in monotherapy. 93% of the acquisition cost
of capecitabine was offset by lower docetaxel costs for
total added costs of $1,341. Cost per quality-adjusted
year of life (QALY) gained with CD was $5,520. The 5th
and 95th percentiles of cost-effectiveness were $4,400
and $11,600, respectively. 
CONCLUSIONS: Combining capecitabine with doc-
etaxel is cost-effective compared with docetaxel
monotherapy in anthracycline-pretreated patients, by CD
signiﬁcantly prolonging time to progression and overall
survival and lowering treatment-related hospitalization
days. The results of the simulation analyses provide 
assurance that combination therapy is likely to be cost-
effective when applied to non-trial settings.
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OBJECTIVES: We performed a pharmacoeconomic 
evaluation of LHRH agonists (LAs) in treating metasta-
tic prostate cancer compared to standard care, as identi-
ﬁed in the literature and by clinical experts, including:
estrogens (DES), orchiectomy, antiandrogens (AAs), and
combinations therapy (LAs + AAs). 
METHODS: A Markov model was constructed to
perform a cost-utility analysis (CUA) over 5 years, from
a Canadian provincial healthcare payer perspective.
Treatment efﬁcacy was determined by meta-analysis of
published clinical data, and utilities were derived from the
literature. 
RESULTS: In the base case analysis, DES was least costly
($588) but also least effective (0.52 QALYs). Orchiec-
tomy ($830 for 0.92 QALYs), with an incremental 
cost-utility ratio of $615/QALY versus DES, dominated
LAs ($8,116 for 0.75 QALYs) and AAs ($4,108 for 
0.62 QALYs). Treatment with combination therapy was 
the most costly at $18,029 and the most effective 
(1.04 QALYs), with an expected incremental ratio
